Prodrugs of itaconic acid and 1- and 4-methyl itaconic acid and their use for treating a disease, disorder, or condition associated with inflammation are disclosed.

The application provides a novel triester compound and the pharmaceutical composition and formulation thereof, as well as a method of using the triester compound for the treatment of, inter alia, an inflammatory-related disease or disorder.

The application provides a novel triester compound and the pharmaceutical composition and formulation thereof, as well as a method of using the triester compound for the treatment of, inter alia, an inflammatory-related disease or disorder.

A compound of Formula (I): ##STR00001##
or a pharmaceutically acceptable salt thereof, in which Ring X is a 3 to 7 membered monocyclic ring, at least one of R.sub.1, R.sub.2, R.sub.3, and R.sub.4 is OR.sub.5 or CH.sub.2OR.sub.5 and the other R.sub.1, R.sub.2, R.sub.3, and R.sub.4 each independently are halogen, OH, OR.sub.5, CH.sub.2OR.sub.5, CO.sub.2H, OCOR.sub.6, (CO)R.sub.6, R.sub.6, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, H, or absent. Also provided herein are therapeutic uses of the compound of Formula (I).

A compound of Formula (I): ##STR00001##
or a pharmaceutically acceptable salt thereof, in which Ring X is a 3 to 7 membered monocyclic ring, at least one of R.sub.1, R.sub.2, R.sub.3, and R.sub.4 is OR.sub.5 or CH.sub.2OR.sub.5 and the other R.sub.1, R.sub.2, R.sub.3, and R.sub.4 each independently are halogen, OH, OR.sub.5, CH.sub.2OR.sub.5, CO.sub.2H, OCOR.sub.6, (CO)R.sub.6, R.sub.6, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, H, or absent. Also provided herein are therapeutic uses of the compound of Formula (I).